PDF下载 ( 2224 KB)
Expression and significance of the LONP1 gene in hepatocellular carcinoma
-
摘要: 目的探讨LONP1基因在肝细胞癌（HCC）组织中的表达情况及临床意义。方法选取由上海芯超生物有限公司提供的在2010年1月-2011年9月病理确诊为HCC的患者90例,根据LONP1蛋白在HCC癌组织中阳性表达程度,分为弱阳性组（n=33）、阳性组（n=24）、强阳性组（n=33）。用免疫组化的方法检测LONP1在癌及癌旁组织中的表达情况,并分析与HCC临床病理特征的关系。计数资料组间比较采用χ2检验或Fisher确切概率法。生存分析采用Kaplan-Meier方法及log-rank检验,影响因素分析采用Cox比例风险回归模型。结果 LONP1蛋白在HCC癌组织中的阳性表达率显著高于癌旁组织（100%vs 8. 9%,χ2=152. 308,P <0. 001）。LONP1蛋白的表达与肿瘤有无包膜、有无合并肝硬化、临床分期和病理分级有关（P值均<0. 05）。弱阳性组中位生存期40. 545个月,阳性组28. 545个月,强阳性组19. 428个月,差异有统计学意义（χ2=32. 058,P <0. 0...Abstract: Objective To investigate the expression and clinical significance of the LONP1 gene in hepatocellular carcinoma( HCC).Methods A total of 90 patients with pathologically confirmed HCC from January 2010 to September 2011 were enrolled,and the microarrays for their HCC tissue and adjacent tissue samples were provided by Shanghai Xinchao Biological Co.,Ltd. According to the level of positive expression of LONP1 in HCC tissue,the patients were divided into weak positive group with 33 patients,positive group with 24 patients,and strong positive group with 33 patients. Immunohistochemistry was used to measure the expression of LONP1 in HCC and adjacent tissue samples,and its association with the clinicopathological features of HCC was analyzed. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Kaplan-Meier method and the log-rank test were used for survival analysis,and the Cox proportional-hazards regression model was used to investigate risk factors. Results The positive expression rate of LONP1 protein in HCC tissue was significantly higher than that in the adjacent tissue( 100% vs 8. 9%,χ2= 152. 308,P < 0. 001). The expression of LONP1 protein was associated with presence or absence of tumor capsule,presence or absence of liver cirrhosis,clinical stage,and pathological grade( all P < 0. 05). There was a significant difference in median survival time between the weak positive group,the positive group,and the strong positive group( 40. 545 months vs 28. 545 months vs 19. 428 months,χ2= 32. 058,P < 0. 001). In HCC patients,median survival time was correlated with the expression of LONP1 protein,pathological grade,and clinical stage( all P < 0. 05). The multivariate Cox analysis showed that with the weak positive expression of LONP1 protein as a reference,positive expression of LONP1 protein( hazard ratio [HR]= 0. 109,95% confidence interval [CI]: 0. 034-0. 349,P < 0. 001) and strong positive expression of LONP1 protein( HR =0. 448,95% CI: 0. 219-0. 918,P = 0. 028) were independent influencing factors for the survival of HCC patients. Conclusion The expression level of LONP1 in HCC tissue is significantly higher than that in adjacent tissue,and the patients with high expression of LONP1 have a significantly shorter survival time than those with low expression.
-
Key words:
- carcinoma,hepatocellular /
- LONP1 /
- prognosis
-
[1] CHEN WQ,ZHENG RS,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. [2] BULTEAUAL,SZWEDA LI,FRIGUET B. Mitochondrial protein oxidation and degradation in response to oxidative stress and aging[J]. Exp Gerontol,2006,41(7):653-657. [3] TATSUTA T. Protein quality control in mitochondria[J]. J Biochem,2009,146(4):455-461. [4] GIBELLINI L,LOSI L,de BIASI S,et al. LONP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells[J]. Front Oncol,2018,8:254. [5] NIE XB,LI M,LU B,et al. Down-regulating overexpressed human lon in cervical cancer suppresses cell proliferation and bioenergetics[J]. PLo S One,2013,8(11):e81084. [6] LIU Y,LAN L,HUANG K,et al. Inhibition of Lon blocks cell proliferatiaon,enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer:potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer[J]. Oncotarget,2014,5(22):11209-11224. [7] National Health and Family Planning Commission of the People’s Repubilc of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431. [8] Chinese Society of Liver Cancer,Chinese Anti-Cancer Association; Liver Cancer Study Group,Chinese Society of Pathology,Chinese Medical Association; Chinese Society of Pathology,Chinese Anti-Cancer Association,et al. Standardized pathological diagnosis guidelines for primary liver cancer(2015)[J]. J Clin Hepatol,2015,31(6):833-839.(in Chinese)中国抗癌协会肝癌专业委员会，中华医学会肝病学分会肝癌学组，中国抗癌协会病理专业委员会，等．原发性肝癌规范化病理诊断指南(2015年版)[J]．临床肝胆病杂志，2015,31(6):833-839. [9] WANG YP,TANG DX. Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients[J]. Int J Clin Exp Med,2015,8(1):1080-1086. [10] CHENG CW,KUO CY,FAN CC,et al. Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species[J]. Cell Death Dis,2013,4:e681. [11] GIBELLINI L,PINTI M,BORALDI F,et al. Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells[J]. FASEB J,2014,28(12):5122-5135. [12] GILLIES RJ,GATENBY RA. Adaptive landscapes and emergent phenotypes:Why do cancers have high glycolysis?[J].J Bioenerg Biomembr,2007,39(3):251-257. [13] BULTEAU AL,BAYOT A. Mitochondrial proteases and cancer[J]. Biochim Biophys Acta,2011,1807(6):595-601. 期刊类型引用(4)
1. 冯婧，高洪燕，黄山. 生化指标及自身抗体对原发性胆汁性肝硬化的诊断价值. 分子诊断与治疗杂志. 2021(07): 1039-1042 . 
百度学术2. 刘蓉，陈清，熊美娥. 肝硬化门静脉高压患者的超声特点. 中国当代医药. 2019(22): 141-143 . 百度学术3. 董征. 原发性胆汁性肝硬化与病毒性肝炎肝硬化超声诊断的对比研究. 当代医学. 2019(29): 105-107 . 百度学术4. 杨璐萍，朱宗国，张然. 原发性胆汁性肝硬化患者免疫功能及肝功能损伤情况研究. 国际检验医学杂志. 2017(18): 2543-2545 . 百度学术其他类型引用(2)
-
百度学术
下载:
